Sugi Predict

Sugi Predict / Compounds / SCHEMBL2255490

SCHEMBL2255490

SCHEMBL2255490

O=C(O)Cn1c(=O)[nH]c2ccccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.62
▸ CYP1A2 P05177 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ APEX1 P27695 1/20 0.58
▸ LMNA P02545 3/20 0.54
▸ HPGD P15428 3/20 0.54
▸ HTT P42858 2/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ MAPT P10636 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ KDM4E B2RXH2 4/20 0.53
▸ DAO P14920 1/20 0.53
▸ GLA P06280 1/20 0.53
▸ IDO1 P14902 1/20 0.50
▸ HTR7 P34969 1/20 0.50
▸ MPO P05164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21463358 0.85 LMNA (0.71) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL10833993 0.85 MEN1 (0.65) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL31653996 0.83 GRIA1 (0.63) MEN1KMT2AAPEX1LMNAKDM4E
SCHEMBL4704936 0.83 GRIA1 (0.63) MEN1KMT2AAPEX1LMNAKDM4E
SCHEMBL4313671 0.83 HPGD (0.68) MEN1CYP1A2KMT2AAPEX1LMNA
SCHEMBL14665126 0.82 CYP1A2 (0.66) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL7231747 0.81 KDM4E (0.67) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL30530511 0.81 MAPK1 (0.70) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL97551 0.81 MAPK1 (0.70) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL14664135 0.81 MEN1 (0.59) MEN1CYP1A2KMT2ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454525-B2 IL4I1 inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-10-28 — — US disclosed
EP-4577543-A1 PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER Redx Pharma Limited (GB) 2025-07-02 — — EP disclosed
CN-119768403-A Pyridopyrazoles as DDR inhibitors for the treatment of fibrotic disorders and cancer 莱德克斯制药有限公司 2025-04-04 — — CN disclosed
US-20240408107-A1 LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2024-12-12 — — US disclosed
CN-115836054-B IL4I1 inhibitors and methods of use 默沙东有限责任公司 2024-12-10 — — CN disclosed
WO-2024042316-A1 PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER REDX PHARMA PLC. (GB) 2024-02-29 — — WO disclosed
WO-2024042316-A1 PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER REDX PHARMA PLC. (GB) 2024-02-29 — — WO disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 — — US disclosed
WO-2023060134-A1 LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-04-13 — — WO disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 — — CN disclosed
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2003-11-06 — — US disclosed
EP-1343499-A2 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-09-17 — — EP disclosed
WO-2003053344-A2 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 — — WO disclosed
US-6506738-B1 Treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection. BRISTOL-MYERS SQUIBB COMPANY 2003-01-14 — — US disclosed
WO-2002062290-A2 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-15 — — WO disclosed
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2002-07-25 — — US disclosed
WO-2002026228-A1 BENZIMIDAZOLONE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-04-04 — — WO disclosed
EP-0350163-A2 Renin inhibitory peptides BEECHAM GROUP PLC (GB) 1990-01-10 — — EP disclosed
EP-0019440-A1 Benzimidazolone derivatives, process for their preparation and pharmaceutical compositions containing them PFIZER INC. (US) 1980-11-26 — — EP disclosed
US-4209527-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1980-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents MAVS, ZC3HAV1, EIF2AK2 MEN1 3967/4885CYP1A2 1326/4885KMT2A 417/4885
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 MEN1 1034/4885CYP1A2 1172/4885KMT2A 3013/4885
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents MAVS, ZC3HAV1, EIF2AK2 MEN1 4565/4885CYP1A2 1430/4885KMT2A 249/4885
US-20240408107-A1 LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PKM, PDK3 MEN1 3857/4885CYP1A2 3256/4885KMT2A 1636/4885
US-12454525-B2 IL4I1 inhibitors and methods of use IL4I1, IL4, IL2 MEN1 1034/4885CYP1A2 1172/4885KMT2A 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.